Clinical Trial Results:
An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) (“XELOX”) versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin with Intravenous Oxaliplatin (Q2W) (“FOLFOX4”) as Treatment for Patients with Metastatic Colorectal Cancer who have Received Prior Treatment with CPT- 11 in Combination with 5-FU/LV as First Line Therapy.
Summary
|
|
EudraCT number |
2004-001685-40 |
Trial protocol |
SK |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
30 Aug 2025
|
First version publication date |
30 Aug 2025
|
Other versions |
|
Summary report(s) |
NO16967 - CTgov Results Receipt |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.